Midodrine Substipharm (Midodrine Hydrochloride)

Midodrine is a prodrug that is converted in the body to desglymidodrine, which selectively stimulates α1‑adrenergic receptors on peripheral blood vessels. This stimulation causes vasoconstriction, raising peripheral resistance and consequently increasing arterial blood pressure, especially when a person is upright.

The appropriate dose of Midodrine Substipharm is determined by the prescribing healthcare professional based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to blood pressure measurements and patient-specific factors.

Safety data for Midodrine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers should discuss individual risks and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Midodrine differs from agents such as fludrocortisone, which increase blood volume, by directly causing vasoconstriction via α1‑adrenergic activation. This results in a faster onset of blood pressure elevation, making it useful for patients who need rapid symptom control, whereas fludrocortisone may be preferred for chronic volume‑expansion strategies.

Midodrine Substipharm should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date indicated on the label.

Midodrine Substipharm is taken orally, usually with a full glass of water. It is commonly prescribed to be taken during the day, avoiding doses close to bedtime to reduce the risk of supine hypertension. Patients should follow the dosing schedule provided by their prescriber.

The most serious risks include supine hypertension, which can lead to cardiovascular complications, and severe bradycardia. Patients should monitor blood pressure while lying down and report any symptoms such as chest pain, severe headache, or palpitations to their healthcare provider promptly.

Midodrine is contraindicated in patients with severe organic heart disease, acute renal failure, or known hypersensitivity to the drug. It should also be avoided in individuals with uncontrolled hypertension or those taking other potent vasopressors without medical supervision.